Patents by Inventor Maciej Pawlowski
Maciej Pawlowski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170239237Abstract: This invention concerns pyrroloquinoline derivatives as antagonists of 5-HT6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in schizophrenia, anxiety, depression, maniac depression, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, panic attacks, attention deficit hyperactivity disorder, attention deficit disorder, Parkinson's disease, Huntington's disease, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, obesity and type-2 diabetes, functional bowel disorder, Irritable Bowel Syndrome. The compounds have the general formula (XIV), wherein the symbols have the meanings given in the description.Type: ApplicationFiled: May 5, 2017Publication date: August 24, 2017Inventors: Pawel ZAJDEL, Katarzyna GRYCHOWSKA, Maciej PAWLOWSKI, Anna PARTYKA, Anna WESOLOWSKA, Andrzej J. BOJARSKI, Piotr POPIK, Tomasz KOS, Grzegorz SATALA, Frederic LAMATY, Evelina COLACINO, Jean MARTINEZ, Gilles SUBRA, Xavier BANTREIL
-
Patent number: 9676772Abstract: This invention concerns pyrroloquinoline derivatives as antagonists of 5-HT6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in schizophrenia, anxiety, depression, maniac depression, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, panic attacks, attention deficit hyperactivity disorder, attention deficit disorder, Parkinson's disease, Huntington's disease, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, obesity and type-2 diabetes, functional bowel disorder, Irritable Bowel Syndrome. The compounds have the general formula (XIV), wherein the symbols have the meanings given in the description.Type: GrantFiled: July 25, 2013Date of Patent: June 13, 2017Assignees: Uniwersyter Jagiellonski, Instytut Farmakologii Polskiej Akademii Nauk, Centre National De La Recherche Scientifique, Universite de MontpellierInventors: Pawel Zajdel, Katarzyna Grychowska, Maciej Pawlowski, Anna Partyka, Anna Wesolowska, Andrzej J. Bojarski, Piotr Popik, Tomasz Kos, Grzegorz Satala, Frederic Lamaty, Evelina Colacino, Jean Martinez, Gilles Subra, Xavier Bantreil
-
Publication number: 20160159790Abstract: This invention concerns pyrroloquinoline derivatives as antagonists of 5-HT6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in schizophrenia, anxiety, depression, maniac depression, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, panic attacks, attention deficit hyperactivity disorder, attention deficit disorder, Parkinson's disease, Huntington's disease, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, obesity and type-2 diabetes, functional bowel disorder, Irritable Bowel Syndrome. The compounds have the general formula (XIV), wherein the symbols have the meanings given in the description.Type: ApplicationFiled: July 25, 2013Publication date: June 9, 2016Applicants: Uniwersytet Jagiellonski, Instytut Farmakologii Polskiej Akademii Nauk, Centre National De La Recherche Scientifique, Universite de MontpellierInventors: Pawel ZAJDEL, Katarzyna GRYCHOWSKA, Maciej PAWLOWSKI, Anna PARTYKA, Anna WESOLOWSKA, Andrzej J. BOJARSKI, Piotr POPIK, Tomasz KOS, Grzegorz SATALA, Frederic LAMATY, Evelina COLACINO, Jean MARTINEZ, Giles SUBRA, Xavier BANTREIL
-
Publication number: 20150051257Abstract: Sulphonamide derivatives of benzylamine of formula (I), wherein A represents phenyl unsubstituted or substituted; or 9- or 10-membered bicyclic group, linked to —(O)x—(CH2)y— through one of its aromatic carbon atoms, consisting of benzene ring fused with -membered heteroaromatic ring containing 1 or 2 heteroatoms independently selected from the group consisting of N and O, wherein such bicyclic group is unsubstituted or substituted or with 5- or 6-membered non-aromatic heterocyclic ring having 1 or 2 O atoms, wherein heterocyclic ring is unsubstituted or substituted with one or more C1-C3-alkyls; D represents a group selected from: phenyl unsubstituted or substituted; naphthyl unsubstituted or substituted; thiophene unsubstituted or substituted; bicyclic group consisting of imidazolering fused with 5-membered non-aromatic carbocyclic ring; bicyclic group consisting of benzene ring fused with 5-membered heteroaromatic ring, having 1 or 2 heteroatoms independently selected from the group consisting of N, O andType: ApplicationFiled: March 20, 2013Publication date: February 19, 2015Applicant: ADAMED SP. ZO.OInventors: Marcin Kolaczkowski, Monika Marcinkowska, Adam Bucki, Tomasz Lysakowski, Maciej Pawlowski
-
Patent number: 8822517Abstract: Arylsulphonamide derivatives of formula (I) and pharmaceutically acceptable salts thereof. The compounds may be useful for the treatment and/or prevention of disorders of the central nervous system.Type: GrantFiled: September 16, 2011Date of Patent: September 2, 2014Assignee: Adamed SP. Z O.O.Inventors: Marcin Kolaczkowski, Piotr Kowalski, Jolanta Jaśkowska, Monika Marcinkowska, Katarzyna Mitka, Adam Bucki, Anna Wesolowska, Maciej Pawlowski
-
Publication number: 20140135310Abstract: Sulphonamide derivatives of alicyclic amines of formula (I), wherein A represents naphthyl or 9- or 10-membered bicyclic group, consisting of benzene ring fused with 5- or 6-membered heterocyclic ring; D represents phenyl, naphthyl, 5-membered aromatic heterocyclic group, bicyclic group consisting of a ring selected from benzene and pyridine, fused with aromatic or non-aromatic 5-membered heterocyclic ring; p, r independently represent 0 or 1; x, z independently represent 1 or 2; n is 2 or 3; and enancjomers, pharmaceutically acceptable salts and solvates thereof. The compounds may be useful for the treatment and/or prevention of the central nervous system disorders.Type: ApplicationFiled: June 29, 2012Publication date: May 15, 2014Applicant: Adamed Sp. z o.o.Inventors: Marcin Kolaczkowski, Monika Marcinkowska, Adam Bucki, Maciej Pawlowski, Andrzej Krukowski, Rafal Rusiecki, Agata Magdalena Siwek, Malgorzata Anna Wolak
-
Publication number: 20140121216Abstract: Indoleamine derivatives of formula (IA), R1 represents benzyl unsubstituted or substituted with halogen atom, —OH, or C1-C3-alkyl; phenylsulphonyl unsubstituted or substituted in the phenyl ring with halogen atom, —OH or C1-C3-alkyl; G1 represents phenoxyalkyl, heteroaryloxyalkyl- or heterocyclyloxyalkyl-piperazine moiety; and pharmaceutically acceptable salts and solvates thereof. The compounds may be useful for the treatment and/or prevention of the central nervous system disorders.Type: ApplicationFiled: June 28, 2012Publication date: May 1, 2014Applicant: Adamed Sp. z o.o.Inventors: Marcin Kolaczkowski, Monika Marcinkowska, Adam Bucki, Maciej Pawlowski, Grzegorz Kazek, Marek Bednarski, Anna Wesolowska
-
Patent number: 8546533Abstract: The present invention relates to a pipecolic linker and its use as a solid-phase linker in organic synthesis. Said pipecolic solid-phase linker may be used for coupling functional groups chosen between primary amines, secondary amines, aromatic amines, alcohols, phenols and thiols. In particular, said pipecolic solid-phase linker may be used for peptide or pseudopeptide synthesis, such as the reverse N to C peptide synthesis or the retro-inverso peptide synthesis, or for the synthesis of small organic molecules.Type: GrantFiled: August 28, 2009Date of Patent: October 1, 2013Assignees: Centre National de la Recherche Scientifique (CNRS), Universite de Montpellier 1, Universite Jagellone, Universite Montpellier 2—Sciences et TechniquesInventors: Jean Martinez, Pawel Zajdel, Maciej Pawlowski, Gilles Subra
-
Publication number: 20130172365Abstract: Arylsulphonamide derivatives of formula (I) and pharmaceutically acceptable salts thereof. The compounds may be useful for the treatment and/or prevention of disorders of the central nervous system.Type: ApplicationFiled: September 16, 2011Publication date: July 4, 2013Applicant: ADAMED SP. Z.O.O.Inventors: Marcin Kolaczkowski, Piotr Kowalski, Jolanta Jaskowska, Monika Marcinkowska, Katarzyna Mitka, Adam Bucki, Anna Wesolowska, Maciej Pawlowski
-
Publication number: 20110152464Abstract: The present invention relates to a pipecolic linker and its use as a solid-phase linker in organic synthesis. Said pipecolic solid-phase linker may be used for coupling functional groups chosen between primary amines, secondary amines, aromatic amines, alcohols, phenols and thiols. In particular, said pipecolic solid-phase linker may be used for peptide or pseudopeptide synthesis, such as the reverse N to C peptide synthesis or the retro-inverso peptide synthesis, or for the synthesis of small organic molecules.Type: ApplicationFiled: August 28, 2009Publication date: June 23, 2011Applicant: UNIVERSITE DE MONTPELLIER IInventors: Jean Martinez, Pawel Zajdel, Maciej Pawlowski, Gilles Subra